CN113577526B - Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system - Google Patents
Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system Download PDFInfo
- Publication number
- CN113577526B CN113577526B CN202110846176.9A CN202110846176A CN113577526B CN 113577526 B CN113577526 B CN 113577526B CN 202110846176 A CN202110846176 A CN 202110846176A CN 113577526 B CN113577526 B CN 113577526B
- Authority
- CN
- China
- Prior art keywords
- drug
- drug delivery
- module
- subcutaneous
- delivery device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 85
- 238000007920 subcutaneous administration Methods 0.000 title claims abstract description 56
- 238000012544 monitoring process Methods 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 165
- 229940079593 drug Drugs 0.000 claims abstract description 115
- 238000001727 in vivo Methods 0.000 claims abstract description 20
- 239000000599 controlled substance Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 8
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001502 supplementing effect Effects 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 4
- -1 perfluoropropyl methyl Chemical group 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 238000001647 drug administration Methods 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 8
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 6
- 238000004026 adhesive bonding Methods 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010033675 panniculitis Diseases 0.000 description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 238000005370 electroosmosis Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
Abstract
The invention relates to the field of medical equipment, and particularly discloses a subcutaneous drug delivery device and a subcutaneous drug delivery monitoring system, which comprise a shell, and a drug delivery control module, a wireless signal transceiver module, a power supply coil, a drug tank, a drug driving module, a drug delivery channel and a drug storage tank which are arranged in the shell. The subcutaneous drug delivery device is matched with the external intelligent terminal to realize wireless power supply and in-vivo drug delivery, a built-in battery is not needed, the structure is compact, the size is small, and meanwhile, after the subcutaneous drug delivery device is implanted, the percutaneous puncture microneedle is not needed to be used for subcutaneous injection of drugs, so that the drug delivery microneedle does not need to be replaced frequently, the safety is improved, and the pain of a patient is reduced.
Description
Technical Field
The invention relates to the field of medical equipment, and particularly discloses a subcutaneous drug delivery device and a subcutaneous drug delivery monitoring system.
Background
The subcutaneous administration is a mode of delivering drugs locally or systemically in vivo through subcutaneous capillaries of skin, realizes the administration of disease treatment, and can be used for long-term treatment of psychosis such as diabetes, allergic dermatosis, epilepsy, chronic diseases such as cardiovascular diseases and digestive system diseases. Because subcutaneous administration can bypass the first pass effect of the liver, has no gastrointestinal damage, can furthest reduce the concentration attenuation of the medicine, can reduce toxic and side effects, and improves the medication efficiency. However, due to the subcutaneous tissue, the drug needs to permeate the layer of barrier, and skin sweating, external pollution and the like are added, so that the drug transdermal permeation and absorption speed is limited, the treatment effect is poor, and even the skin is damaged. The transdermal puncture microneedle improves the transdermal drug delivery efficiency to a certain extent, and the microneedle is pricked into the subcutaneous tissue to directly deliver the drug from the outside of the skin to subcutaneous tissue fluid, so that the process of penetrating and diffusing the drug into the subcutaneous tissue through skin tissues is reduced, but the drug loading quantity of the microneedle is small, the microneedle drug delivery device needs to be replaced frequently, and the operation is inconvenient.
Disclosure of Invention
The present invention aims to solve, at least to some extent, the above-described technical problems in the related art. Therefore, the invention provides a subcutaneous drug delivery device and a subcutaneous drug delivery monitoring system, which solve at least one technical problem.
In order to achieve the above object, according to a first aspect of the present invention, there is provided a subcutaneous drug delivery device, including a housing, and a drug delivery control module, a wireless signal transceiver module, a power supply coil, a drug reservoir, a drug delivery channel, and a drug storage reservoir disposed in the housing, wherein the drug delivery control module is connected to the wireless signal transceiver module, the power supply coil, and the drug drive module, the drug drive module is connected to the drug reservoir, for driving the drug reservoir to deliver drugs, a drug outlet of the drug reservoir is connected to the drug delivery channel, and the drug storage reservoir is connected to the drug reservoir.
The invention provides a subcutaneous drug administration monitoring system, which comprises an intelligent terminal and the subcutaneous drug administration device, wherein the intelligent terminal comprises a control module, a wireless signal receiving and transmitting module and a transmitting coil, and the wireless signal receiving and transmitting module and the transmitting coil are connected with the control module.
In a third aspect the present invention provides a method of monitoring using a subcutaneous administration monitoring system as described above, comprising the steps of:
determining that the in-vivo index information meets abnormal conditions, controlling a wireless signal receiving and transmitting module to transmit a drug delivery instruction to a wireless signal receiving and transmitting module of the subcutaneous drug delivery device, and simultaneously controlling a transmitting coil of the intelligent terminal to wirelessly supply power to a power supply coil, wherein a drug delivery control module controls a drug driving module to drive a drug pool to deliver drugs according to the drug delivery instruction;
and determining that the in-vivo index information meets the normal condition, and controlling the intelligent terminal to stop working. In addition, the subcutaneous administration device of the present invention may have the following additional technical features:
according to some embodiments of the invention, the drug drive module is selected from an electronically controlled drug drive module, wherein the electronically controlled drug drive module is selected from an electroosmotic drug drive module, a piezoelectric drug drive module, and an electromagnetic drug drive module.
According to some embodiments of the invention, the drug driving module is selected from a temperature control type drug driving module, a temperature sensor connected with the drug administration control module and a heating module connected with the power supply coil and the drug administration control module are arranged on the temperature control type drug driving module, the temperature control type drug driving module comprises a phase change body and a flexible film arranged at the bottom of the phase change body, and the flexible film is in contact with the upper liquid surface of the drug tank.
According to some embodiments of the invention, the material of the phase-change body is selected from perfluoropropyl methyl ester and medical paraffin, and the material of the flexible film is selected from any one of polyurethane, polymethyl methacrylate and polycarbonate.
According to some embodiments of the invention, the drug outlet of the drug reservoir is provided with a first one-way valve.
According to some embodiments of the invention, the subcutaneous drug delivery device further comprises an in vivo indicator sensor coupled to the drug delivery control module.
According to some embodiments of the invention, the drug delivery channel is funnel-shaped, the drug delivery channel has a large open end and a small open end, the drug reservoir is disposed at the large open end of the drug delivery channel, and the first one-way valve is disposed at the small open end of the drug delivery channel.
According to some embodiments of the invention, a dosing tube is arranged between the drug storage tank and the drug tank, and a second one-way valve is arranged on the dosing tube.
According to some embodiments of the invention, the subcutaneous drug delivery device further comprises an external drug supplementing channel communicated with the drug storage tank, wherein an opening is formed in the bottom of the drug storage tank, and a piston is arranged at the opening.
According to some embodiments of the invention, the smart terminal is a watchband type, a belly band type or a sucker type smart terminal.
According to some embodiments of the invention, the method further comprises a monitoring terminal in wireless communication with the intelligent terminal.
According to some embodiments of the invention, the driving mode of the drug driving module is selected from any one of electroosmosis type, piezoelectric type and electromagnetic type.
According to some embodiments of the invention, the step of the drug administration control module controlling the drug drive module to drive the drug reservoir to expel the drug according to the drug administration instructions comprises:
the drug administration control module controls the heating module to heat the drug driving module;
acquiring a temperature value of a medicine driving module;
determining that the temperature value meets the power regulation condition of the heating module, and controlling the subcutaneous drug delivery device to send a power regulation instruction to the intelligent terminal;
and controlling the output power of the transmitting coil according to the power regulating instruction. Compared with the prior art, the invention has the following beneficial effects:
1. the subcutaneous drug delivery device is matched with the external intelligent terminal to realize wireless power supply and in-vivo drug delivery, a built-in battery is not needed, the structure is compact, the size is small, and meanwhile, after the subcutaneous drug delivery device is implanted, the percutaneous puncture microneedle is not needed to be used for subcutaneous drug injection, so that the drug delivery microneedle does not need to be frequently replaced, the safety is improved, and the pain of a patient is reduced;
2. the medicine in the subcutaneous medicine delivery device can enter human blood through the capillary vessel, so that the function of local medicine delivery or medicine delivery to the whole body is realized, the medicine effect is improved, and the time for exerting the medicine effect is shortened.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are required in the embodiments or the description of the prior art will be briefly described, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to the structures shown in these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a schematic view showing an internal structure of a subcutaneous administration device in an embodiment of the present invention;
FIG. 2 is a schematic diagram of a subcutaneous administration monitoring system in accordance with one embodiment of the present invention;
FIG. 3 is a schematic diagram showing the state of drug supplementation of a subcutaneous drug delivery monitoring system in accordance with another embodiment of the present invention;
fig. 4 is a schematic view showing a drug administration state of a subcutaneous drug administration monitoring system according to another embodiment of the present invention.
The achievement of the objects, functional features and advantages of the present invention will be further described with reference to the accompanying drawings, in conjunction with the embodiments.
Detailed Description
Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. While exemplary embodiments of the present disclosure are shown in the drawings, it should be understood that the present disclosure may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
It is to be understood that the terminology used herein is for the purpose of describing particular example embodiments only, and is not intended to be limiting. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. The terms "comprises," "comprising," and "having" are inclusive and therefore specify the presence of stated features, elements, and/or components, but do not preclude the presence or addition of one or more other features, elements, components, and/or groups thereof.
In the description of the present invention, unless explicitly stated and limited otherwise, the terms "disposed" and "connected" should be interpreted broadly, and may be, for example, fixedly connected, detachably connected, or integrally connected; can be directly connected or indirectly connected through an intermediate medium. The specific meaning of the above terms in the present invention can be understood by those skilled in the art according to the specific circumstances.
Furthermore, the terms "first," "second," and the like, are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defining "a first", "a second", or the like, may include one or more such features, either explicitly or implicitly. In the description of the present invention, the meaning of "plurality" means at least two, for example, two, three, etc., unless specifically defined otherwise.
For ease of description, spatially relative terms, such as "bottom," "front," "upper," "inclined," "lower," "top," "inner," "horizontal," "outer," and the like, may be used herein to describe one element or feature's relationship to another element or feature as illustrated in the figures. Such spatially relative terms are intended to encompass different orientations of the mechanism in use or operation in addition to the orientation depicted in the figures. For example, if the mechanism in the figures is turned over, elements described as "below" or "beneath" other elements or features would then be oriented "above" or "over" the other elements or features. Thus, the example term "below … …" may include both upper and lower orientations.
Referring to fig. 1-4, an embodiment of the present invention provides a subcutaneous drug delivery monitoring system, which includes a subcutaneous drug delivery device 100, a monitoring terminal and an intelligent terminal, wherein the subcutaneous drug delivery device 100 can perform wireless data communication with an external intelligent terminal, the monitoring terminal can perform wireless data communication with the intelligent terminal, the intelligent terminal can be an external machine 200, and the external machine 200 can be a strap type, a belly strap type or a sucking disc type, and is worn on one side of the subcutaneous drug delivery device 100 corresponding to a subcutaneous position, so as to facilitate wireless power supply and instruction transmission to the subcutaneous drug delivery device 100. The subcutaneous drug delivery device 100 comprises a shell 10, and a drug delivery control module 11, a wireless signal receiving and transmitting module, a power supply coil 12, a drug tank 13, a drug driving module 14, a drug delivery channel 15 and a drug storage tank 16 which are arranged in the shell 10, wherein the drug delivery control module 11 is connected with the wireless signal receiving and transmitting module, the power supply coil 12 and the drug driving module 14, the drug driving module 14 is connected with the drug tank 13 and used for driving the drug tank 13 to deliver drugs, a drug outlet of the drug tank 13 is communicated with the drug delivery channel 15, and the drug storage tank 16 is communicated with the drug tank 13.
In order to realize information interaction between the intelligent terminal and the subcutaneous drug delivery device 100 and between the intelligent terminal and the monitoring terminal, the monitoring terminal in this embodiment includes an information acquisition module, an instruction transceiver module, and a first control module connected to the information acquisition module and the instruction transceiver module, where the information acquisition module may be an in vivo index sensor, and is used to acquire in vivo index information, and the intelligent terminal may include a second control module, and a wireless signal transceiver module connected to the second control module, and a transmitting coil 201. Specifically, the in-vivo index sensor transmits the acquired in-vivo index information to the first control module, the first control module controls the instruction receiving and sending module to send an instruction to the wireless signal receiving and sending module of the intelligent terminal, the first control module judges the in-vivo index information, if the in-vivo index information is determined to be abnormal, the first control module sends the instruction to the external machine 200, the external machine 200 realizes wireless power supply to the drug delivery control module 11 through the transmitting coil 201 and the power supply coil 12, and transmits a control instruction to the drug delivery control module 11 through the wireless signal receiving and sending module, the drug delivery control module 11 controls the drug driving module 14 to drive the drug pool 13 to deliver drugs, when the in-vivo index information is normal, the first control module controls the instruction receiving and sending module to send a stop instruction to the wireless signal receiving and sending module of the intelligent terminal, the intelligent terminal stops sending the instruction to the external machine 200, and the subcutaneous drug delivery device 100 stops working, so that feedback is formed.
It should be noted that in some other embodiments of the present invention, the monitoring terminal is not necessary, and the information acquisition module may be directly integrated in the intelligent terminal, so that in vivo index information may be directly acquired by the intelligent terminal, and administration may be controlled according to the in vivo index information.
In other embodiments of the present invention, the in-vivo index sensor may also be disposed in the subcutaneous administration device 100, that is, the in-vivo index sensor connected to the administration control module 11 is disposed in the housing 10, and administration is achieved by self-control of the subcutaneous administration device 100, where the extracorporeal machine 200 may only perform a wireless power supply function.
With continued reference to fig. 1-2, in this embodiment, the housing 10 may be divided into two parts, an unpackaged front plate and a housing formed by bonding or gluing other panels, the housing 10 may be made of alumina ceramic, zirconia ceramic, polymethyl methacrylate, etc., the power supply coil 12 is fixed on the top plate of the housing 10 by gluing, and is connected to the administration control module 11 by a power supply wire 17, the administration control module 11 (with a control circuit inside) is fixed on the rear plate of the housing 10 by gluing, welding, etc., the wireless signal transceiver module transmits the received signal of the external machine 200 to the administration control module 11, the administration control module 11 sends an electrical signal to the drug driving module 14 through the first lead 18, the outside of the administration control module 11 is a biocompatible housing, and the optional material is alumina ceramic, zirconia ceramic, polymethyl methacrylate, etc.
In this embodiment, with continued reference to fig. 2, the administration channel 15 is funnel-shaped, and the administration channel 15 is made of polyether ether ketone, polymethyl methacrylate, polytetrafluoroethylene, or the like, and is fixed to the bottom plate of the housing 10 by gluing, welding, or the like. Wherein, the administration channel 15 has a large opening end and a small opening end, the medicine pond 13 is arranged at the large opening end of the administration channel 15, the medicine outlet of the medicine pond 13 is provided with a first one-way valve 19, and the first one-way valve 19 is positioned at the small opening end of the administration channel 15. Specifically, the first check valve 19 includes a protrusion 190 on the bottom plate of the housing 10 and a movable piece 191 movably disposed at the small opening end of the administration channel 15, a circle of groove 150 is formed around the inner surface of the small opening end of the administration channel 15, the movable piece 191 is slidably disposed in the groove 150, when the medicine tank 13 discharges medicine, the movable piece 191 moves downward under the thrust action of the medicine liquid, so as to realize the opening of the first check valve 19, otherwise, the movable piece 191 restores to the original state, so as to realize the closing of the first check valve 19, prevent the body fluid and medicine from flowing backward, and ensure the safety of medicine administration.
Further, a medicine adding pipe 20 is arranged between the medicine storage tank 16 and the medicine storage tank 13, a second one-way valve 21 is arranged on the medicine adding pipe 20, so that medicine can only flow from the medicine storage tank 16 to the medicine storage tank 13, the medicine storage tank 16 can be made of materials such as alumina ceramic, zirconia ceramic, polymethyl methacrylate and the like, the medicine storage tank 16 is fixed on a bottom plate of the shell 10 in a gluing, bonding and other modes, an opening is formed in the bottom of the medicine storage tank 16, a piston 22 is arranged at the opening, an external medicine supplementing channel 23 is arranged at the top end of the medicine storage tank 16, when the medicine liquid in the medicine storage tank 16 is reduced, the pressure of the medicine storage tank 16 can be reduced, and at the moment, the piston 22 can move upwards to maintain the pressure in the medicine storage tank 16, so that medicine can be conveniently added into the medicine storage tank 13 and medicine can be supplemented into the medicine storage tank 16 through the external medicine supplementing channel 16.
With continued reference to fig. 2, the drug driving module 14 in this embodiment is selected from an electrically controlled drug driving module, wherein the electrically controlled drug driving module is selected from an electroosmosis type drug driving module, a piezoelectric type drug driving module and an electromagnetic type drug driving module, wherein the material of the housing of the drug driving module 14 is polyurethane, polymethyl methacrylate, polycarbonate, etc., and the upper part thereof is connected with the drug reservoir 13 by gluing. Specifically, when the monitoring terminal detects that the index in the body is abnormal, an instruction is sent to the external machine 200, the external machine 200 wirelessly supplies power to the drug delivery control module 11 through the power supply coil 12 and sends a signal, the drug delivery control module 11 controls the electric control type drug driving module, the electric control type drug driving module can use electroosmosis, piezoelectricity, electromagnetism and other modes to deliver drugs outwards, when the drugs in the drug tank 13 are reduced, the pressure is reduced, and the drugs in the drug storage tank 16 are automatically supplemented into the drug tank 13. When the monitoring terminal detects that the in-vivo index is normal, the monitoring terminal stops sending instructions to the external machine 200, and the subcutaneous drug delivery device 100 stops working, so that feedback is formed.
In other embodiments of the present invention, with continued reference to fig. 3-4, the drug driving module 14 is selected from a temperature-controlled drug driving module, a temperature sensor 24 connected to the drug administration control module 11 and a heating module connected to the power supply coil 12 and the drug administration control module 11 are disposed on the temperature-controlled drug driving module, the heating module is used for heating the drug driving module 14, the temperature sensor 24 is fixed on the drug driving module 14, the temperature-controlled drug driving module includes a phase-change body 140 and a flexible film 141 disposed at the bottom of the phase-change body 140, and the flexible film 141 is in contact with the upper liquid surface of the drug pool 13. Specifically, the material of the phase-change body 140 is selected from perfluoropropyl methyl ester and medical paraffin, and the material of the flexible film 141 is selected from any one of polyurethane, polymethyl methacrylate and polycarbonate. In addition, the temperature sensor 24 is fabricated using MEMS technology for measuring the temperature of the drug drive module 14 in real time and transmitting data to the drug delivery control module 11 via the first lead 18.
With continued reference to fig. 4, when the monitoring terminal detects that the human index is abnormal, an instruction is sent to the external machine 200, the external machine 200 supplies power to the power supply coil 12 through the transmitting coil 201, the drug delivery control module 11 controls the heating module to heat the drug driving module 14, the temperature of the drug driving module 14 is increased after the drug driving module 14 is heated, the volume is increased, the flexible film 141 of the drug driving module 14 is expanded downwards, the drug in the drug pool 13 is extruded, the purpose of drug delivery is achieved, and the drug delivery control module 11 determines that the temperature value meets the power regulation condition of the heating module by receiving and processing the temperature value detected by the temperature sensor 24 because the volume of the drug driving module 14 changes along with the temperature change, and controls the subcutaneous drug delivery device to send the power regulation instruction to the external machine 200; the external machine 200 controls the output power of the transmitting coil 201 according to the power adjusting instruction so as to adjust the heating power of the heating module, thereby controlling the temperature of the medicine driving module 14, controlling the expansion degree of the flexible film 141 and realizing the timing and quantitative conveying of the medicine.
As shown in fig. 3, when the monitoring terminal detects that the in-vivo index is normal, the in-vitro machine 200 stops working, the temperature of the medicine driving module 14 is reduced, the flexible film 141 is contracted, and the medicine in the medicine storage tank 16 is sucked into the medicine tank 13 through the second one-way valve 21 to supplement the medicine.
In addition, after the assembly and connection of the components in the housing 10 are completed, an adhesive filler may be injected into the housing 10 to further fix the positions of the components and to make the connection between the components more stable.
The present invention is not limited to the above-mentioned embodiments, and any changes or substitutions that can be easily understood by those skilled in the art within the technical scope of the present invention are intended to be included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (9)
1. The subcutaneous drug delivery device is characterized by comprising a shell, a drug delivery control module, a wireless signal receiving and transmitting module, a power supply coil, a drug pool, a drug driving module, a drug delivery channel and a drug storage pool, wherein the drug delivery control module is arranged in the shell, the drug delivery control module is connected with the wireless signal receiving and transmitting module, the power supply coil and the drug driving module, the drug driving module is connected with the drug pool and is used for driving the drug pool to deliver drugs, a drug outlet of the drug pool is communicated with the drug delivery channel, and the drug storage pool is communicated with the drug pool; a medicine outlet of the medicine pond is provided with a first one-way valve, a medicine adding pipe is arranged between the medicine storage pond and the medicine pond, and a second one-way valve is arranged on the medicine adding pipe; the subcutaneous drug delivery device further comprises an external drug supplementing channel communicated with the drug storage tank, the external drug supplementing channel comprises a first tube and a second tube which are sequentially connected with the drug storage tank, the inner diameter of the second tube is gradually reduced from one end far away from the first tube to one end close to the first tube, the inner diameter of the first tube is equal to the inner diameter of one end, close to the first tube, of the second tube, an opening is formed in the bottom of the drug storage tank, and a piston is arranged at the opening.
2. The subcutaneous drug delivery device according to claim 1, wherein the drug drive module is selected from an electronically controlled drug drive module, wherein the electronically controlled drug drive module is selected from an electroosmotic drug drive module, a piezoelectric drug drive module, and an electromagnetic drug drive module.
3. The subcutaneous drug delivery device according to claim 1, wherein the drug drive module is selected from a temperature controlled drug drive module, a temperature sensor connected with the drug delivery control module and a heating module connected with the power supply coil and the drug delivery control module are arranged on the temperature controlled drug drive module, the temperature controlled drug drive module comprises a phase change body and a flexible film arranged at the bottom of the phase change body, and the flexible film is in contact with the upper liquid surface of the drug pool.
4. The subcutaneous drug delivery device according to claim 3, wherein the material of the phase change body is selected from perfluoropropyl methyl ester and medical paraffin, and the material of the flexible film is selected from any one of polyurethane, polymethyl methacrylate and polycarbonate.
5. The subcutaneous drug delivery device according to claim 1, further comprising an in vivo indicator sensor coupled to the drug delivery control module.
6. The subcutaneous drug delivery device according to claim 1, wherein the drug delivery channel is funnel-shaped, the drug delivery channel has a large open end and a small open end, the drug reservoir is disposed at the large open end of the drug delivery channel, and the first one-way valve is disposed at the small open end of the drug delivery channel.
7. A subcutaneous drug delivery monitoring system, comprising an intelligent terminal and a subcutaneous drug delivery device according to any one of claims 1-6, wherein the intelligent terminal comprises a control module, and a wireless signal transceiver module and a transmitting coil connected with the control module.
8. The subcutaneous drug delivery monitoring system as in claim 7, wherein the smart terminal is a watchband, a belly-band, or a suction-cup smart terminal.
9. The subcutaneous drug delivery monitoring system as in claim 7, further comprising a monitoring terminal in wireless communication with the intelligent terminal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110846176.9A CN113577526B (en) | 2021-07-26 | 2021-07-26 | Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110846176.9A CN113577526B (en) | 2021-07-26 | 2021-07-26 | Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113577526A CN113577526A (en) | 2021-11-02 |
| CN113577526B true CN113577526B (en) | 2023-11-17 |
Family
ID=78250113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110846176.9A Active CN113577526B (en) | 2021-07-26 | 2021-07-26 | Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113577526B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102090876A (en) * | 2011-03-04 | 2011-06-15 | 上海交通大学 | In-vitro magnetic-controlled medicament delivery capsule system based on wireless energy supply |
| CN103585689A (en) * | 2013-11-11 | 2014-02-19 | 上海移宇科技有限公司 | Disposable non-catheter insulin pump |
| CN204017140U (en) * | 2014-07-24 | 2014-12-17 | 河南科技大学 | A kind of ultrasonic micropin compound transdermal delivery device |
| CN207575546U (en) * | 2017-02-27 | 2018-07-06 | 曲松涛 | A kind of dept. of dermatology's liquid medicine applicator |
| CN213190307U (en) * | 2020-08-15 | 2021-05-14 | 任俊业 | Continuous drencher special for veterinarian |
| CN112933392A (en) * | 2021-03-12 | 2021-06-11 | 南昌工程学院 | Microneedle transdermal drug delivery system based on micro-piezoelectric pump thermal drive coupling accurate control |
| CN213698500U (en) * | 2020-07-29 | 2021-07-16 | 河南省儿童医院郑州儿童医院 | Infant respiratory tract nursing administration device |
-
2021
- 2021-07-26 CN CN202110846176.9A patent/CN113577526B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102090876A (en) * | 2011-03-04 | 2011-06-15 | 上海交通大学 | In-vitro magnetic-controlled medicament delivery capsule system based on wireless energy supply |
| CN103585689A (en) * | 2013-11-11 | 2014-02-19 | 上海移宇科技有限公司 | Disposable non-catheter insulin pump |
| CN204017140U (en) * | 2014-07-24 | 2014-12-17 | 河南科技大学 | A kind of ultrasonic micropin compound transdermal delivery device |
| CN207575546U (en) * | 2017-02-27 | 2018-07-06 | 曲松涛 | A kind of dept. of dermatology's liquid medicine applicator |
| CN213698500U (en) * | 2020-07-29 | 2021-07-16 | 河南省儿童医院郑州儿童医院 | Infant respiratory tract nursing administration device |
| CN213190307U (en) * | 2020-08-15 | 2021-05-14 | 任俊业 | Continuous drencher special for veterinarian |
| CN112933392A (en) * | 2021-03-12 | 2021-06-11 | 南昌工程学院 | Microneedle transdermal drug delivery system based on micro-piezoelectric pump thermal drive coupling accurate control |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113577526A (en) | 2021-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11744937B2 (en) | Flexible and conformal patch pump | |
| JP7122948B2 (en) | drug delivery device | |
| US20110060280A1 (en) | Adhesive skin patch with pump for subcutaneous drug delivery | |
| EP2865325B1 (en) | Skin-adherable cradle for infusion pump or continuous blood glucose monitor having optical indication means | |
| JP2005523397A (en) | Plunger of fluid dosing device | |
| CA2830453C (en) | Dermally affixed device for intravenous access | |
| CN113577526B (en) | Subcutaneous drug delivery device and subcutaneous drug delivery monitoring system | |
| KR20230071340A (en) | Reservoir assembly and apparatus for infusing medical liquid comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |